Eris Lifesciences Limited has informed the Exchange regarding a press release dated March 20, 2026, "Launch of Generic Semaglutide under the Brand "Sundae" in India.".
ERIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Eris Lifesciences has announced a strategic partnership with Natco Pharma to commercialise generic Semaglutide in India, to be marketed under the brand name 'Sundae'. Natco has already received approval from the drug regulator CDSCO to manufacture the product, with the launch expected in March 2026. Semaglutide is a GLP-1 receptor agonist used for Type 2 diabetes and chronic weight management — a fast-growing therapeutic segment globally. The partnership leverages Eris's strong diabetes franchise and commercial reach alongside Natco's manufacturing and complex formulation capabilities. Eris posted FY25 revenue of ₹2,894 crore, with revenue and operating profit growing 2.6x over the last five years.
This move positions Eris to tap into India's expanding GLP-1 and metabolic care market, potentially driving incremental revenue growth in its core diabetes segment. The product approval and imminent launch could be a positive catalyst for the stock, though actual revenue contribution will depend on pricing, uptake, and competition from other generic semaglutide launches.